CURRICULUM VITAE

(ESMO-ID: 81500)

(ASCO-ID: 272603)

(IASLC-ID: 424795)

(IAP-ID: L/2014/B-1368)

(PHO-ID: L/2014/794)

(INPOG/R/2015/22)

Personal Details

Name : Dr. Bivas Biswas

Qualifications : MBBS, MD (Pediatrics, AIIMS),

DM (Medical Oncology, AIIMS)

ORCID ID : 0000-0002-6101-5500

Education and Qualifications:

S.No. Degree University Year

1. MBBS Calcutta Medical College,

Calcutta University, Calcutta, India

1999-2005

2. Junior Resident

(Neurosurgery)

Calcutta Medical College,

Calcutta University, Calcutta, India

2005-2006

3. M.D.(Pediatric

Medicine)

All India Institute Medical Sciences, New

Delhi, India

2006-2009

4. Senior Resident All India Institute Medical Sciences, New 2009-2010

(Medical Oncology) Delhi, India

5. D.M. (Medical

Oncology)

All India Institute of Medical Sciences

(AIIMS), New Delhi, India

2010-2013

Work experience:

1. Junior residency (non-academic) in Neurosurgery, Calcutta Medical College. From

May’2005- Feb’2006

2. Junior Residency (MD Pediatrics), AIIMS, New Delhi: from July’2006 – June’2009

3. Senior residency (non-academic) in Medical Oncology, AIIMS, New Delhi. From

July’2009 – June’2010

4. Senior resident (DM Medical Oncology), AIIMS, New Delhi: from July’2010 –

June’2013

5. Consultant (Medical Oncology), Apollo Gleneagles Hospital. 58, Canal Circular Road,

Kolkata-700054. From July’2013 – May’2014.

6. Consultant (Medical Oncology), Tata Medical Center, Action Area I, Newtown, New

Town, Kolkata - 700160, West Bengal. From June’2014 – Nov’2015.

7. Assistant Professor in Department of Medical Oncology, Dr. B.R.A. I.R.C.H, AIIMS,

New Delhi-110029. From Dec’2015 – June’2016.

8. Current workplace (Since July’16): Consultant Medical Oncologist at Tata Medical

Center, Action Area I, Newtown, New Town, Kolkata - 700160, West Bengal.

Awards and achievements:

1. Gold medal in Pediatrics (MBBS)

2. Shakuntala Jolly Gold medal in Medical Oncology (DM course)

3. Passed European Society for Medical Oncology (ESMO) Exam 2012

4. Awarded European Society for Medical Oncology (ESMO) Translational Research Unit

(TRU) fellowship on 21st – 24

th October’2013

5. Received ISMPO award in 1st Indian Cancer Congress (ICC)’2013

6. Awarded SIOP Scholarship in the year 2016 to present paper to the 48th Annual meeting of

SIOP in Dublin, Ireland, 16-19th October’2016.

7. Selected in 2016 Australia and Asia Pacific Clinical Oncology Research Development

(ACORD) Workshop

Academic positions:

1. Teacher & mentor for National Board of Examination [DNB] accredited post-doctoral

fellowship program in Medical Oncology

2. Assessor of DNB examination conducted by NBE.

3. Section Editor in Indian Journal of Medical & Pediatric Oncology [IJMPO]

4. Reviewer in Journal of Thoracic Oncology [ JTO], Indian Journal of Pediatrics [IJP], Indian

Journal of Medical & Pediatric Oncology [ IJMPO], BMC cancer, Journal of Urology, BMJ

palliative & supportive care

International travel grants recipients:

1. Awarded International Travel grant from ESMO to participate in ESMO Preceptorship

on Gastric Cancer, 20-21 December” 2013, Singapore

2. Awarded International Travel grant to present paper in “37th ESMO (Vienna, Austria,

2012)” from Department of Science and Technology, Govt. of India

3. Awarded International Travel grant from ESMO to attend “Personalized medicine 2013

- Signalling Pathways Targeting the HER/EGFR family: Focus on breast, lung and

colorectal cancers, 2013, Sitges, Spain”.

4. Awarded International Travel grant to present paper in “ASCO Annual Meeting’2013,

Chicago, USA” from CSIR, Govt. of India.

5. Awarded International Travel grant to present papers in “45th Congress of the

International Society of Paediatric Oncology (SIOP)’ 2013” from ICMR, Govt. of India.

6. Awarded International Travel grant to attend “ESMO Symposium on Immuno-Oncology

2013: Advances in cancer immunotherapy; from vaccines to antibodies and cell therapies”.

7. Awarded International Travel grant from ESMO to participate in “ESMO Preceptorship

on Immuno-oncology, 2-3 October’2015, Prague.

8. Awarded International Travel grant from ESMO to participate in “ESMO Preceptorship

on NSCLC, 13-14 December’2016, Singapore.

9. Awarded International Travel grant from ESMO to participate in “ESMO Preceptorship

on Prostate cancer, 15-16 December’2016, Singapore.

PUBLICATIONS

Original articles:

1. Biswas B, Rastogi S, Khan SA, Shukla NK, Deo SVS, Agarwala S, Mohanti BK, Sharma

MC, S Vishnubhatla, Bakhshi S. Developing a Prognostic Model for Localized Ewing

Sarcoma Family of Tumors: a Single Institutional Experience of 224 Cases Treated with

Uniform Chemotherapy Protocol. J Surg Oncol. 2015;111(6):683-9

2. Biswas B, Thakar A, Mohanti BK, S Vishnubhatla, Bakhshi S. Prognostic factors in head and

neck Ewing sarcoma family of tumors. Laryngoscope. 2015; 125(3):E112-7.

3. Biswas B, Rastogi S, Khan SA, Shukla NK, Deo SVS, Agarwala S, Sharma DN, Thulkar S,

S. Vishnubhatla, Bakhshi S. Hypoalbuminaemia is an Independent Predictor of Poor

Outcome in Metastatic Ewing's Sarcoma Family of Tumours: A Single Institutional

Experience of 150 Cases Treated with Uniform Chemotherapy Protocol. Clin Oncol (R Coll

Radiol). 2014; 26(11): 722–729.

4. Biswas B, Shukla NK, Deo SVS, Agarwala S, Sharma DN, Sreenivas Vishnubhatla, Bakhshi

S. Evaluation of outcome and prognostic factors in Extraosseous Ewing sarcoma. Pediatric

Blood Cancer. 2014; 61(11):1925-31.

5. Biswas B, Rastogi S, Khan SA, Mohanti BK, Sharma DN, Sharma MC, Mridha AR, Bakhshi

S. Outcome and Prognostic Factors in Ewing's family Tumors of the Extremities. J Bone

Joint Surg Am. 2014; 96(10):841-849.

6. Biswas B, Agarwala S, Shukla NK, Deo SVS,

Sharma DN, Thulkar S, Sreenivas

Vishnubhatla, Bakhshi S. Evaluation of outcome and prognostic factors in thoracic primitive

neuroectodermal tumor: a study of 84 cases. Ann Thorac Surg. 2013; 96(6):2006-14.

7. Biswas B, Agarwala S, Rastogi S, Khan SA, Mohanti BK, Sharma DN, Pathy S, Bakhshi S.

High Burden of Metastases and Poor Outcome in Pelvic PNET. Pediatric Blood Cancer.

2013; 60(9):E97-9.

8. Biswas B, Dabkara D, Ganguly S, Ghosh J, Gupta S, Sen S, Chatterjee M, Basu A,

Mukherjee S. (2021) Outcome of testicular non-seminomatous germ cell tumours: report

from a tertiary cancer centre in eastern India. ecancer. 2021; 15 1204

9. Biswas B, Sharma M.C, Mridha AR, Bakhshi S. Expression of Cathepsin L in tumor cells

and tumor associated macrophages in patients with Ewing sarcoma family of tumors: A pilot

study. Indian J Pathol Microbiol 2015, 58(2): 170-74.

10. Biswas B, Bakhshi S. Management of Ewing sarcoma family of tumors: current scenario and

unmet need. World J Orthop. 2016; 7(9): 527-538.

11. Biswas B, Dabkara D, Sengupta M, Ganguly S, Ghosh J, Arunsingh S M, Sen S.

Multimodality treatment outcome in patients with primary malignant mediastinal germ cell

tumor in adults. Cancer Rep (Hoboken). 2020 Oct 8:e1306. doi: 10.1002/cnr2.1306.

12. Patel A, Batra

U, Prasad

KT, Dabkara

D, Ghosh

J, Sharma

M, Singh N,

Suresh P, Jain

P, Malik

PS, Choudhary

P, Ganguly

S, Khurana

S, Shivashankara Ms

,

Bothra N, Muthu

V, Biswas B. Real world experience of treatment and outcome in ALK-

rearranged metastatic non-small cell lung cancer: A multicenter study from India. Current

Problems in Cancer; Mar’2020 [DOI: 10.1016/j.currproblcancer.2020.100571].

13. Prasad KT, Muthu

V, Biswas

B, Malik

PS, Dabkara

D, Ganguly

S, Ghosh

J, Kataria

B,

Khurana S, Verma

S, Singh N. Utility and safety of maintenance chemotherapy in advanced

non–small cell lung cancer across various performance status categories: real-world

experience. Current Problems in Cancer; Mar’2020

[DOI: 10.1016/j.currproblcancer.2020.100565].

14. Arora N, Mukherjee G, Biswas B, Gupta P, Saha K, Vinarkar S, Banerjee S, Chowdhury S.S,

Parihar M, Midha D, Lingegowda D, Chatterjee S, Arunsingh S M, Ganguly S, Dabkara D,

Mishra DK. Next generation sequencing in Lung cancer: An Initial Experience from India.

Current Problems in Cancer; Feb’2020 [DOI: 10.1016/j.currproblcancer.2020.100562]. 

15. Kumar S, Joga S, Biswas B, Dabkara D, Prasad KT, Singh N, Malik PS, Khurana S, Ganguly

S, Muthu V, Batra U. Immune checkpoint inhibitors in advanced non–small cell lung cancer:

A metacentric experience from India. Current Problems in Cancer; Jan’2020

[DOI: 10.1016/j.currproblcancer.2020.100549].

16. Sharma A, Kataria B, Biswas B, Bakhshi S, Pushpam D. Oral metronomic chemotherapy is a

cost effective alternative to pazopanib in advanced soft tissue sarcoma. Journal of Oncology

Pharmacy Practice. March 2021. doi:10.1177/10781552211000113

17. Ghosh J, Chatterjee M, Ganguly S, Dabkara D, Biswas B. Outcomes of metastatic

neuroendocrine carcinoma of the gallbladder. ecancer 2021, 15:1174; DOI:

https://doi.org/10.3332/ecancer.2021.1174.

18. Ghosh J, Chatterjee M, Ganguly S, Datta A, Biswas B, Mukherjee G, Agarwal S, Ahmed R,

Chatterjee S, Dabkara D (2021) PDL1 expression and its correlation with outcomes in non-

metastatic triple-negative breast cancer (TNBC) ecancer 15 1217.

19. Ganguly S, Ghosh J, Gehani A, Basu A, Chatterjee M, Dabkara D, Biswas B. Non-small-cell

lung cancer metastasis to unusual sites: A retrospective case series. Cancer Res Stat Treat

2021;4:50-4.

20. Kumar A, Biswas B, Chopra A, Kapil A, Vishnubhatla S, Bakhshi S. Early Discontinuation

versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients with

Febrile Neutropenia, Before Recovery of Counts: A Randomized Controlled Trial (DALFEN

Study). Indian J Pediatr, June 2020.

21. Ghosh J, Ganguly S, Mondal D, Pandey P, Dabkara D, Biswas B. Perspective of Oncology

Patients During COVID-19 Pandemic: A Prospective Observational Study From India. JCO

Global Oncol 6:844-851.

22. Ganguly S, Biswas B, Bhattacharjee S, Ghosh J, Mukhopadhyay S, Midha D, Dabkara D.

Clinocopathological characteristics and treatment outcome in small cell lung cancer: a single

institutional experience from India. Lung India, 37 (2), 134-139

[10.4103/lungindia.lungindia_370_19]

23. Puspam D, Garg V, Ganguly S, Biswas B. Management of Refractory Pediatric Sarcoma:

Current Challenges and Future Prospects. OncoTargets and Therapy 13:5093-5112.

24. Dabkara D, Ganguly S, Ghosh J, Mukherjee S, Gupta S, Mallick I, Mukherjee S, Midha D,

Chatterjee M, Basu A, Hasan A, Biswas B. Clinico-pathological characteristics, prognostic

factors and treatment outcomes of seminomatous germ cell tumors from a tertiary cancer

center in Eastern India. Natl Med J India. 2019 (in press).

25. Biswas B, Ghadyalpatil N, Krishna MV, Deshmukh J. A review on adverse event

profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell

lung cancer patients. Indian J Cancer. 2017 Dec; 54(Supplement):S55-S64. doi:

10.4103/ijc.IJC_589_17.

26. Biswas B, Sharma A, Makharia GK, Thulkar S, Arava S, Bahl A, Chaudhary S.

Immunoproliferative small intestinal disease: report of 6 cases. Tropical Gastroenterology

2014; 35(4):269–272.

27. Prabhash K, Advani SH, Batra U, Biswas B, Chougule A, Ghosh M, Muddu VK, Sahoo TP,

Vaid A. Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for

Molecular Testing. Advances in Therapy, March 2019 [DOI: 10.6084/m9.figshare.7680170

28. Verma H, Sehgal K, Panchal K.B, Chakraborty S, Biswas B, Mukherjee G, Midha D, Biswas

G. Presentation and Management of Dermatofibrosarcoma Protuberans: A Single Center

Protocol. Indian J of Surg Oncol, 11(1):35-40. doi: 10.1007/s13193-019-01007-3.

29. Ghosh A, Ghosh J, Midha D, Banerjee P, Chakraborti B, Roy A, Rai S, Mathai S, Ganguly

S, Dabkara D, Biswas B, Bhaumik J. Clinical and Pathological Characteristics and Outcomes

of Clear Cell Carcinoma of Ovary: A Tertiary Cancer Centre Data. Indian Journal of

Gynecologic Oncology, December 2019 [DOI: 10.1007/s40944-019-0314-1].

30. Patel A, Tiwari A, Biswas B, Sharma MC, Vishnubhatla S, Bakhshi S. Clinical Predictors

and Prognostic Model for Pediatric Lymphoblastic Lymphoma Treated with Uniform BFM90

Protocol: A Single-Center Experience of 65 Patients from Asia. Clinical lymphoma,

myeloma & leukemia, 19(6) [DOI: 10.1016/j.clml.2019.01.008].

31. Bakhshi S, Batra A, Biswas B, Dhawan D, Paul R, Sreenivas V. Aprepitant as an Add-on

Therapy in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double

Blind, Placebo-Controlled Trial. Support Care Cancer. 2015; 23(11):3229-37.

32. Hari P, Biswas B, Pandey R, Kalaivani M, Kumar R, Bagga A. Updated height- and

creatinine-based equation and its validation for estimation of glomerular filtration rate in

children from developing countries. Clin Exp Nephrol. 2012; 16(5): 697-705.

33. Kumar L, Cyriac SL, Tejomurtula TV, Bahl A, Biswas B, Sahoo RK, Mukherjee A, Sharma

O. Autologous Stem Cell Transplantation for Multiple Myeloma: Identification of Prognostic

Factors. Clin Lymphoma Myeloma Leuk. 2013; 13(1): 32-42.

34. Seth A, Mahapatra SK, Nayak B, Saini AK, Biswas B. Primitive neuroectodermal

tumors of kidney: Our experience in a tertiary care center. Indian J Cancer. 2016;

53(1): 109-12.

35. Dabkara D, Ganguly S, Biswas B, Ghosh J. Metronomic therapy in metastatic castrate-

resistant prostate cancer: Experience from a tertiary cancer care center. Indian Journal of

Cancer. 2018 Jan-Mar;55(1):94-97. doi: 10.4103/ijc.IJC_346_17

36. Ganguly S, Biswas B, Ghosh J,Dabkara D. Metastatic stomach cancer: Real world scenario

from a developing country. South Asian Journal of Cancer. 2018 Jul-Sep;7(3):171-174.

doi: 10.4103/sajc.sajc_2_18.

37. Mallick A, Das J, Shaw MK, Biswas B, Ray S. Prognostic value of metabolic tumor

parameters in pretreatment 18F-fluorodeoxyglucose positron emission tomography–

computed tomography scan in advanced non-small cell lung cancer. Indian J Nucl Med

2021;36:107-13.

Review article

1. Dabkara D, Mondal D, Ghosh J, Biswas B, Ganguly S. How I Treat Metastatic Hormone-

Sensitive Prostate Cancer? Ind J Med Paediatr Oncol 2021;42:100–107.

Correspondence:

1. Biswas B, Ganguly S, Ghosh J. Olaparib in Metastatic Castration-Resistant Prostate Cancer.

N Engl J Med. 2021 Mar 25;384(12):1174-1175. doi: 10.1056/NEJMc2100225. PMID:

33761222.

2. Biswas B, Dabkara D, Ganguly S. Survival of patients with metastatic breast cancer with or

without locoregional therapy. Lancet Oncol. 2015 Dec;16(16):e586-7. doi: 10.1016/S1470-

2045(15)00453-2

3. Biswas B, Dabkara D. Bevacizumab in advanced angiosarcoma: what is the reality? J Clin

Oncol. 2016 Mar 1;34(7):764. doi: 10.1200/JCO.2015.64.2181.

4. Biswas B. Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With

Advanced Non–Small-Cell Lung Cancer in the Era of Personalized Medicine. J Clin Oncol.

2015; 33:524.

5. Biswas B, Dabkara D, Ganguly S, G Joydeep, Prasad E. Cytoreductive nephrectomy in

metastatic renal cell carcinoma in the era of targeted therapy: scientifically relevant or natural

selection? J Clin Oncol. 2017 Feb 6:JCO2016708156. doi: 10.1200/JCO.2016.70.8156.

6. Biswas B, Dabkara D, Ganguly S, G Joydeep, Prasad E. Adjuvant chemotherapy for upper

tract urothelial carcinoma: is there sufficient evidence? J Clin Oncol. 2017 May

4:JCO2017728600. doi: 10.1200/JCO.2017.72.8600.

7. Patel A, Gupta VG, Biswas B, Ganguly S, Das CK, Batra A, Bhethanabhotla S. Reply to D.

O'Reilly et al. JCO Global Oncology 2021 :7, 648-648

8. Biswas B, Bakhshi S, Sengupta M. Childhood Ewing sarcoma of orbit: Is it so fatal? J

Pediatr Hematol Oncol. 2016 Jan;38(1):82-3. doi: 10.1097/MPH.0000000000000458.

9. Patel A, Gupta VG, Biswas B, Das CK, Batra A, Ganguly S, Bethanabhotla S. Revisiting

Fulvestrant Dosing in Uncertain Economic Times. JCO Global Oncology no. 7 (2021) 1-3;

DOI: 10.1200/GO.20.00362

10. Batra A, Patel A, Gupta V G, Mehta P, Tilak TVSVGK, Biswas B, Pramanik R, Das C K,

Srivastava P. Oncotype DX: Where Does It Stand in India? Journal of Global Oncology.

July 2019. DOI: 10.1200/JGO.19.00151.

11. Mehta P, Batra A, Patel A, Tannok I, Gupta V G, Tilak TVSVGK, Biswas B, Pramanik R,

Das C K, Drivastava P. Low dose abiraterone in metastatic prostate cancer – is it practice

changing? Facts and Facets. JCO Glob Oncol. 2020 Mar; 6:382-386. doi:

10.1200/JGO.19.00341.

12. Biswas B, Ganguly S, Dabkara D, Ghosh J, Srivastava P, Mehta P, Patel A, Bethanabhotla S,

Batra A, Pramanik R, Gupta VG, Das CK, Mahindru S. How we treat lung cancer during

sars-Cov-2 (COVID-19) pandemic in India? Indian Journal of Medical & Pediatric

Oncology May 2020; DOI: 10.4103/ijmpo.ijmpo_122_20.

13. Srivastava P, Tilak TVSVGK, Patel A, Das CK, Biswas B, Mahindru S, Pramanik R, Ghosh

J, Mehta P. Advisory for cancer patients during the COVID pandemic. Cancer Res Stat

Treat 2020; 3:145‑8.

14. Batra A, Mehta P, Patel A, Bethanabhotla S, Biswas B, Pramanik R, Das CK. Breast cancer

treatment during the COVID-19 pandemic. Indian Journal of Medical & Pediatric

Oncology May 2020; DOI: 10.4103/ijmpo.ijmpo_111_20.

15. Mahindru S, Das CK,Patel A, Mehta P, Biswas B, Batra A, Bandhopadhyay A. Cancer

surgery in challenging time of COVID-19 pandemic – A pragmatic approach. Indian

Journal of Medical & Pediatric Oncology May 2020; DOI: 10.4103/ijmpo.ijmpo_121_20.

16. Bethanabhotla S, Pramanik R, Srivastava P, Mehta P,Patel A, Biswas B, Batra A, Gupta VG,

Das CK, Mahindru S. Colorectal cancer chemotherapy during COVID-19 pandemic. Indian

Journal of Medical & Pediatric Oncology May 2020; DOI: 10.4103/ijmpo.ijmpo_149_20.

17. Das CK, Mahindru S, Patel A, Batra A, Biswas B, Mehta P, Pramanik R, Bethanabhotla S,

Gupta VG. How I treat epithelial ovarian cancer during COVID-19 pandemic. Indian

Journal of Medical & Pediatric Oncology May 2020; DOI: 10.4103/ijmpo.ijmpo_112_20.

18. Pramanik R, Srivastava P, Sharma A, Mehta P, Patel A, Bethanabhotla S, Biswas B, Batra A,

Gupta VG, Das CK, Mahindru S. Management of head-and-neck cancer during COVID-19

crisis: A medical oncology perspective. Indian Journal of Medical & Pediatric Oncology

May 2020; DOI: 10.4103/ijmpo.ijmpo_134_20.

19. Ghosh J, Ganguly S, Biswas B, Dabkara D, Srivastava P, Patel A, Batra A, Mehta P.

Systemic treatment of gastroesophageal cancer during SARS-CoV2. Indian Journal of

Medical & Pediatric Oncology May 2020; DOI: 10.4103/ijmpo.ijmpo_118_20.

20. Patel A, Batra A, Mehta P, Sharma A, Sirohi B, Biswas B, Gupta VG, Ganguly S.

Gallbladder cancer: Adjuvant and palliative treatment during Covid-19 pandemic in India.

Indian Journal of Medical & Pediatric Oncology May 2020; DOI:

10.4103/ijmpo.ijmpo_110_20.

21. Dabkara D, Ganguly S, Ghosh J, Patel A, Batra A, Das Ck, Tilak TVSVGK, Biswas B. How

We Treat Genitourinary Cancers During COVID-19 Pandemic? Asian Pacific Journal of

Cancer Care 5(Supplement 1):147-152.

22. Chatterjee A, Biswas B, Gehani A, Das J, Sen S, Mukhopadhyay S, Chandra A, Ghosh P,

Gupta B, Lingegowda D. Oncoradiology preparedness in the COVID-19 pandemic:

Perspective from a tertiary oncology referral center from Eastern India. Indian J Med

Paediatr Oncol; DOI: 10.4103/ijmpo.ijmpo_240_20.

Editorials:

1. Bakshi S, Biswas B. Cytomegalovirus in Hematological Malignancies. Indian Pediatr.

2013; 50 (2):193-94.

2. Bakshi S, Biswas B. Addressing Controversies in Pediatric Oncology. Indian J Pediatr.

2013; 80(10):844-5.

3. Bakshi S, Biswas B. Advances in Pediatric Cancer Therapy: Potential Applicability in Indian

Scenario. Indian J Pediatr. 2015; 82(4):301-2.

Selected summaries:

1. Biswas B, Rastogi S, Batra A, Ganguly S. Trastuzumab and Lapatinib in HER-2-positive

metastatic colorectal cancer. Natl Med J India; 29 (4): 219-220.

2. Biswas B, Dabkara D, Ganguly S. In-transit metastases from Malignant Melanoma. Natl

Med J India. 2017;30(5): 297.

3. Biswas B, Dabkara D, Ganguly S, Prasad E. Consolidation chemotherapy after concurrent

chemoradiotherapy in locally advanced non-squamous non-small cell lung cancer: When,

whom and how much? Natl Med J India; 30 (1): 26-27.

4. Biswas B, Ganguly S, Ghosh J, Batra A. Sodium thiosulfate on development of cisplatin-

induced hearing loss in children with cancer. Natl Med J India. 2017; 30(6): 337- 328.

Case reports:

1. Chatterjee A, Biswas B, Gehani A, Sen S. Pembrolizumab-induced large duct

cholangiopathy: Diagnosis and follow-up imaging. J Postgrad Med 2021;67(1):43-45.

2. Ghosh J, Ganguly S, Dabkara D, Biswas B, Chatterjee A, Mukhopadhyay S, Banerjee S, Sen

S, Arun I. Pancreatic adenocarcinoma with primary tumor calcification and calcified liver

metastasis: Report of a rare case and review of literature. Indian J Med Paediatr Oncol

2020;41:738-740.

3. Ghosh J, Ganguly S, Dabkara D, Biswas B, Chatterjee A, Mukhopadhyay S, Chandra A, Sen

S, Dey D. Metachronous muscle metastasis in a case of metastatic gallbladder cancer with

TP35 gene mutation: A rare case report. South Asian J Cancer. 2019; 8(4): 240-257.

4. Biswas B, Dabkara D, Mukhopadhyay S. Aspergillus Invading Metastatic Cavity? Annals of

Hematology & Oncology, 22 June’2017: 4(7).

5. Ghosh S, Ganguly S, Ghosh J, Biswas B, Dabkara D. A novel oxaliplatin desensitization

protocol: Short, safe, and effective. Indian J Med Paediatr Oncol 2020;41:287-8.

6. Ghosh J, Das J, Ganguly S,, Biswas B, Dabkara D. Cardiac metastasis from squamous

cell carcinoma of the buccal mucosa: A case report and review of the literature.

Cancer Research Statistics and Treatment 3(3):617 - 619.

7. Basu A, Chatterjee M, Ghosh J, Ganguly S, Biswas B, Dabkara D. Leptomeningeal

metastasis in lung cancer: Not always a gloomy picture. Cancer Research Statistics and

Treatment 3(3):619 - 621.

8. Ganguly S, Alphones S, Ghosh P, Midha D, Ghosh J, Biswas B. Rectal cancer with breast

metastasis: A case report with review of literature. Cancer Res Stat Treat 3(3):627 - 629.

9. Basu A, Chatterjee M, Dabkara D, Biswas B, Ganguly S, Ghosh J, Ghosh P. Adrenal

metastasis in an older patient with seminoma. Cancer Res Stat Treat 2020;3:836-7.

10. Biswas B. November 2016- ESMO image of the month. Available at

http://www.esmo.org/Career-Development/Young-Oncologists-Corner/Image-of-the-

Month/November-2016-Image-of-the-Month.

Drug Review:

1. Ganguly S, Ghosh J, Biswas B, Dabkara D. Ado‑trastuzumab emtansine – The

monoclonal drug conjugate in human epidermal growth factor receptor 2‑positive breast

cancer. Indian J Med Paediatr Oncol 2020;41:218-20.

Research Experience (Dr. Bivas Biswas)

1. Study name Role Phase

2. Estimation of Glomerular Filtration Rate in Children from

Prediction Equation Using Plasma Creatinine and Height

PI MD

dissertation

3. Evaluation of clinico-pathological characteristics, prognostic

factors and treatment outcomes of patients with Ewing’s

sarcoma/PNET

PI DM

(fellowship)

dissertation

4. Expression of Cathepsin L in patients with Ewing’s

sarcoma/PNET and its correlation with clinico-pathological

features and outcome- A retrospective study

PI DM

(fellowship)

dissertation

5. A Phase III, randomized, double-blind, placebo-controlled,

multicenter, international study of osimertinib as maintenance

therapy in patients with locally advanced, unresectable EGFR

mutation-positive Non-Small Cell Lung Cancer (Stage III)

whose disease has not progressed following definitive

platinum-based chemoradiation therapy (LAURA)

PI III

6. A Phase III, Randomised, Double-Blind, Placebo-Controlled,

Multicentre Study of Durvalumab as Consolidation Therapy in

Patients with Locally Advanced, Unresectable, Non-Small Cell

Lung Cancer (Stage III) Who Have Not Progressed following

Definitive, Platinum-Based, Chemoradiation Therapy

(PACIFIC- 5)

PI III

7. A Phase III, Double-blind, Placebo-controlled, Multi-center

International Study of Neoadjuvant/ Adjuvant Durvalumab for

the Treatment Patients with Resectable Stages II and III Non-

small Cell Lung Cancer [AEGEAN]

PI III

8. A Phase II, Single Arm Study Assessing the Efficacy of

Osimertinib in Combination with Savolitinib in Patients with

EGFRm+ and MET+, Locally Advanced or Metastatic Non-

Small Cell Lung Cancer who have Progressed Following

Treatment with Osimertinib (The SAVANNAH Study)

PI II

9. A Phase III, Randomized, Double-blind, Placebo-controlled,

Multi-center, International Study of Durvalumab or

Durvalumab and Tremelimumab as Consolidation Treatment

for Patients with Stage I-III Limited Disease Small-Cell Lung

Cancer Who Have Not Progressed Following Concurrent

Chemoradiation Therapy (ADRIATIC)

PI III

10. A Phase III, Randomized, Open-Label, Controlled, Multi-

Center, Global Study of First-Line Durvalumab in Combination

with Standard of Care Chemotherapy and Durvalumab in

PI III

Combination with Tremelimumab and Standard of Care

Chemotherapy Versus Standard of Care Chemotherapy Alone

in Patients with Unresectable Locally Advanced or Metastatic

Urothelial Cancer [NILE]

11. A randomized, open label, multicenter phase II study

evaluating the efficacy and safety of capmatinib (INC280) plus

pembrolizumab versus pembrolizumab alone as first line

treatment for locally advanced or metastatic non-small cell lung

cancer with PD-L1≥ 50% [CINC280I12201]

PI II

12. PARACHUTE: PAzopanib Real-world Assessment of Clinical

effectiveness and safety in patients wHo have Undergone

Treatment in different sEttings in advanced renal cell

carcinoma; a prospective, non-interventional, observational

study (CPZP034AIC04)

PI IV

13. An Open Label, Single Arm, Multicenter, Safety Study of

Atezolizumab in Locally Advanced or Metastatic Urothelial or

Non-Urothelial Carcinoma of the Urinary Tract (MO29983)

PI III

14. An Observational, multicentre, prospective study to evaluate

concordance of detecting EGFR mutation by circulating tumor

free DNA versus tissue biopsy in NSCLC

(CONCORDANCE)

PI observational

15. A Phase III, Open-label, Randomized Study of

Osimertinib with or without Platinum Plus

Pemetrexed Chemotherapy, as First-line Treatment in

Patients with Epidermal Growth Factor Receptor

(EGFR) Mutation- Positive, Locally Advanced or

Metastatic Non-small Cell Lung Cancer

(FLAURA2).

PI III

16. SINGLE ARM STUDY TO EVALUATE THE SAFETY OF

DACOMITINIB FOR THE FIRST LINE TREATMENT OF

PARTICIPANTS IN INDIA WITH METASTATIC NON

SMALL CELL LUNG CANCER WITH EPIDERMAL

GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING

MUTATIONS

PI IV

17. SINGLE-ARM STUDY TO EVALUATE THE SAFETY OF

LORLATINIB IN ALK INHIBITOR-TREATED

UNRESECTABLE ADVANCED AND/OR RECURRENT

ALK-POSITIVE NON-SMALL CELL LUNG CANCER

PARTICIPANTS IN INDIA

PI IV

18. Safety & efficacy of OSIMERTINIB in Indian patients who

progressed after 1st line 1

st or 2

nd generation TKI with T790M

mutation

Co-PI IV

19. Study of Efficacy and Safety of Canakinumab as Adjuvant

Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-

IIIA and IIIB (T>5cm N2) Completely Resected Non-small

Cell Lung Cancer (CANOPY-A)

Co-PI III

20. A randomized, double-blind, placebo-controlled, phase III

study evaluating the efficacy and safety of pembrolizumab plus

platinum-based doublet chemotherapy with or without

canakinumab as first line therapy for locally advanced or

metastatic non-squamous and squamous non-small cell lung

cancer subjects [CANOPY 1]

Co-PI III

21. A Multicenter Phaase 4, Open-label, Single-arm, Safety and

Efficacy Study of Enzalutamide in Indian Patients with

Progressive Metastatic Castration-resistant Prostate Cancer

(mCRPC) Previously Treated with Docetaxel-Based

Chemotherapy [9785-CL-0413]

Co-PI IV

22. An open label, multicenter, non-comparative, Phase IV study

of Panitumumab to characterize its safety, tolerability and

activity in Indian subjects with previously treated wild type

RAS (KRAS and NRAS) metastatic colorectal cancer

Co-PI IV

23. A Phase III Randomised, Double-Blind, Parallel Group,

Multicentre Study to Compare the Efficacy, Safety,

Pharmacokinetics and Immunogenicity between SB3 (proposed

trastuzumab biosimilar) and Herceptin® in Women with Newly

Diagnosed HER2 Positive Early or Locally Advanced Breast

Cancer in Neoadjuvant Setting

Co-PI III

24. A phase III multicenter, randomized study of oral LDK378

versus standard chemotherapy in previously untreated adult

patients with ALK rearranged (ALK-positive), stage IIIB or IV,

non-squamous non-small cell lung cancer (CLDK378A2301).

ASCEND 4

Co-PI III

Signature Date

30-June-2021